Amyotrophic lateral sclerosis (ALS) is a complex disease characterized by the interplay of genetic and environmental factors for which, despite decades of intense research, diagnosis remains rather delayed, and most therapeutic options fail. Therefore, unravelling other potential pathogenetic mechanisms and searching for reliable markers are high priorities. In the present study, we employ the SOMAscan assay, an aptamer-based proteomic technology, to determine the circulating proteomic profile of ALS patients. The expression levels of similar to 1300 proteins were assessed in plasma, and 42 proteins with statistically significant differential expression between ALS patients and healthy controls were identified. Among these, four were upregulated proteins, Thymus- and activation-regulated chemokine, metalloproteinase inhibitor 3 and nidogen 1 and 2 were selected and validated by enzyme-linked immunosorbent assays in an overlapping cohort of patients. Following statistical analyses, different expression patterns of these proteins were observed in the familial and sporadic ALS patients. The proteins identified in this study might provide insight into ALS pathogenesis and represent potential candidates to develop novel targeted therapies.

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients

Chiorino, Giovanna;Guana, Francesca;Benedetti, Valerio;Calvo, Andrea;Casale, Federico;Manera, Umberto;Favole, Alessandra;Crociara, Paola;Testori, Camilla;Carta, Valerio;Tessarolo, Carlotta;D'Angelo, Antonio;De Marco, Giovanni;Caramelli, Maria;Chiò, Adriano;
2023-01-01

Abstract

Amyotrophic lateral sclerosis (ALS) is a complex disease characterized by the interplay of genetic and environmental factors for which, despite decades of intense research, diagnosis remains rather delayed, and most therapeutic options fail. Therefore, unravelling other potential pathogenetic mechanisms and searching for reliable markers are high priorities. In the present study, we employ the SOMAscan assay, an aptamer-based proteomic technology, to determine the circulating proteomic profile of ALS patients. The expression levels of similar to 1300 proteins were assessed in plasma, and 42 proteins with statistically significant differential expression between ALS patients and healthy controls were identified. Among these, four were upregulated proteins, Thymus- and activation-regulated chemokine, metalloproteinase inhibitor 3 and nidogen 1 and 2 were selected and validated by enzyme-linked immunosorbent assays in an overlapping cohort of patients. Following statistical analyses, different expression patterns of these proteins were observed in the familial and sporadic ALS patients. The proteins identified in this study might provide insight into ALS pathogenesis and represent potential candidates to develop novel targeted therapies.
2023
24
3
1899
1906
ALS; SOMAscan; TARC; TIMP-3; nidogen; plasma proteins
Berrone, Elena; Chiorino, Giovanna; Guana, Francesca; Benedetti, Valerio; Palmitessa, Claudia; Gallo, Marina; Calvo, Andrea; Casale, Federico; Manera, Umberto; Favole, Alessandra; Crociara, Paola; Testori, Camilla; Carta, Valerio; Tessarolo, Carlotta; D'Angelo, Antonio; De Marco, Giovanni; Caramelli, Maria; Chiò, Adriano; Casalone, Cristina; Corona, Cristiano
File in questo prodotto:
File Dimensione Formato  
Int J Mol Sci 2023 - Berrone - SOMAscan proteomics in ALS.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 2.81 MB
Formato Adobe PDF
2.81 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1904350
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact